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BACKGROUND
In the ISCHEMIA trial, an invasive strategy with angiographic assessment and re-
vascularization did not reduce clinical events among patients with stable ischemic 
heart disease and moderate or severe ischemia. A secondary objective of the trial 
was to assess angina-related health status among these patients.
METHODS
We assessed angina-related symptoms, function, and quality of life with the Seattle 
Angina Questionnaire (SAQ) at randomization, at months 1.5, 3, and 6, and every 
6 months thereafter in participants who had been randomly assigned to an invasive 
treatment strategy (2295 participants) or a conservative strategy (2322). Mixed-
effects cumulative probability models within a Bayesian framework were used to 
estimate differences between the treatment groups. The primary outcome of this 
health-status analysis was the SAQ summary score (scores range from 0 to 100, 
with higher scores indicating better health status). All analyses were performed in 
the overall population and according to baseline angina frequency.
RESULTS
At baseline, 35% of patients reported having no angina in the previous month. 
SAQ summary scores increased in both treatment groups, with increases at 3, 12, 
and 36 months that were 4.1 points (95% credible interval, 3.2 to 5.0), 4.2 points 
(95% credible interval, 3.3 to 5.1), and 2.9 points (95% credible interval, 2.2 to 3.7) 
higher with the invasive strategy than with the conservative strategy. Differences 
were larger among participants who had more frequent angina at baseline (8.5 vs. 
0.1 points at 3 months and 5.3 vs. 1.2 points at 36 months among participants 
with daily or weekly angina as compared with no angina).
CONCLUSIONS
In the overall trial population with moderate or severe ischemia, which included 35% 
of participants without angina at baseline, patients randomly assigned to the invasive 
strategy had greater improvement in angina-related health status than those assigned 
to the conservative strategy. The modest mean differences favoring the invasive strat-
egy in the overall group reflected minimal differences among asymptomatic patients 
and larger differences among patients who had had angina at baseline. (Funded by 
the National Heart, Lung, and Blood Institute and others; ISCHEMIA ClinicalTrials 
.gov number, NCT01471522.)
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T
he principal goals of treating pa-
tients with stable ischemic heart disease 
are to prolong survival, prevent disease 
progression, and optimize patients’ health sta-
tus: their symptoms, function, and quality of life. 
To prevent death and myocardial infarctions, 
secondary prevention with lifestyle and pharma-
cologic intervention is recommended for all pa-
tients with stable ischemic heart disease.1,2 Al-
though the incremental utility of revascularization, 
as compared with modern guideline-based med-
ical therapy alone, for improving prognosis in 
patients with stable ischemic heart disease has 
been unsettled, guidelines and appropriate-use 
criteria endorse revascularization for the relief of 
symptoms that are not adequately controlled with 
medical therapy.3,4
Previous studies of invasive strategies in which 
percutaneous coronary intervention was used in 
the management of stable ischemic heart disease 
have shown a transient health-status benefit as 
compared with a conservative strategy,5 although 
a more durable benefit after coronary-artery by-
pass grafting (CABG) has been observed.6 These 
studies, however, were performed in an era before 
drug-eluting stents and often did not include the 
option of CABG, and patients underwent random-
ization after the coronary anatomy had been de-
fined. To formally evaluate strategies for manag-
ing substantial ischemia in high-risk patients, the 
International Study of Comparative Health Effec-
tiveness with Medical and Invasive Approaches 
(ISCHEMIA) randomly assigned patients with 
moderate or severe ischemia to receive treatment 
with either an initially invasive strategy involving 
angiographic assessment and revascularization 
(when feasible) along with guideline-based med-
ical therapy or an initially conservative strategy 
of guideline-based medical therapy alone.7 The 
primary analysis in the main trial, which is now 
reported in the Journal,8 showed no benefit of an 
invasive strategy with respect to clinical events 
over a median of 3.2 years of observation. In this 
report, we document the health-status outcomes 
of these two treatment strategies in high-risk pa-
tients with stable ischemic heart disease, a key 
secondary outcome of the trial.
Me thods
Trial Population
Details of the trial and the assessments of the 
patients’ health status have been described pre-
viously.7,9 Details of the eligibility criteria, treat-
ment assignments, treatment received (including 
anti-anginal therapy), and follow-up are reported 
by Maron et al.8
Health-Status Outcomes
To quantify symptoms, function, and quality of 
life among the participants who underwent ran-
domization, a brief symptom survey was admin-
istered before randomization, at months 1.5, 3, 
and 6, and every 6 months thereafter until ter-
mination of the trial. This survey included the 
Seattle Angina Questionnaire (SAQ), the Rose Dys-
pnea Scale,10 and the visual analogue scale of the 
European Quality of Life–5 Dimensions (EQ-5D).11 
Linguistically and culturally certified translations 
of the SAQ (www . cvoutcomes . org) were used in 
each participating country. The 7-item version of 
the SAQ was the primary instrument used for 
the analyses of health status7,12 (see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). It is a shortened ver-
sion of the original 19-item SAQ and has been 
shown to be highly valid, reliable, and sensitive 
to clinical change.13-15 The SAQ captures the fre-
quency of angina (SAQ Angina Frequency score) 
and the disease-specific effect of angina on pa-
tients’ physical function (SAQ Physical Limitation 
score) and quality of life (Quality of Life score) 
over the previous 4 weeks; these scores are aver-
aged to obtain the SAQ Summary score, an over-
all measure of patients’ stable ischemic heart 
disease–specific health status. SAQ scores range 
from 0 to 100, with higher scores indicating less 
frequent angina, better function, and better qual-
ity of life. To support clinical interpretation, the 
SAQ Summary score, SAQ Physical Limitation 
score, and SAQ Quality of Life score can be cat-
egorized into ranges of 0 to 24 (very poor to 
poor health status), 25 to 49 (poor to fair), 50 to 
74 (fair to good), and 75 to 100 (good to excel-
lent).16,17 SAQ Angina Frequency scores of 0 to 30, 
31 to 60, 61 to 99, and 100 have been shown to 
validly reflect angina that occurs daily, weekly, 
several times per month (“monthly”), and no 
angina, respectively, as assessed with daily dia-
ries.18 These ranges of SAQ scores are strongly 
and independently correlated with the risk of 
subsequent death, the risk of myocardial infarc-
tion, and health care costs.16,19 The Rose Dyspnea 
Scale has four items indicating whether patients 
experience breathlessness with different activi-
ties (scores range from 0 to 4, with higher scores 
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indicating dyspnea with milder activities). For 
the EQ-5D visual analogue scale, patients rate 
their current health along a continuum from 0, 
indicating the worst possible health state, to 100, 
indicating the best possible health state. Addi-
tional health-status domains, as described in the 
protocol (available at NEJM.org), were used in a 
subset of sites and are not reported here.
Trial Oversight and Organization
The analyses of data on health status were spon-
sored by the National Heart, Lung, and Blood 
Institute, with additional support from industry 
for the main trial.8 An independent data and 
safety monitoring board approved the trial pro-
tocol and monitored the safety of the partici-
pants. The protocol was approved by the institu-
tional review boards of the New York University 
Grossman School of Medicine, Duke University, 
Saint Luke’s Hospital, and each participating site. 
All participants from the 320 sites provided writ-
ten informed consent. The health-status assess-
ments were designed by the authors and approved 
by the trial leadership, the National Heart, Lung, 
and Blood Institute, and the data and safety 
monitoring board. All analyses of health status 
were conducted at Saint Luke’s Mid America 
Heart Institute, which had a data confidentiality 
agreement with the data coordinating center. 
The first author vouches for the accuracy and com-
pleteness of the data on health status and for the 
fidelity of this analysis of health-status outcomes 
to the protocol.
Statistical Analysis
The original and final protocol and statistical 
analysis plan are available at NEJM.org. The sta-
tistical analysis plan was finalized in September 
2019, after the feasibility of the planned analyses 
had been confirmed in a preliminary pooled, 
blinded data set that did not indicate treatment 
assignments. All analyses were conducted on an 
intention-to-treat basis.
The primary outcome was the SAQ Summary 
score. The prespecified plan was to provide results 
both for the overall population and the popula-
tion stratified according to baseline angina fre-
quency, as defined by the SAQ Angina Frequency 
score.12 Additional exploration of the heteroge-
neity of the treatment benefit according to pa-
tients’ baseline characteristics is ongoing and is 
not reported here. Although the analyses included 
all available assessments through 78 months, we 
present the results through the first 48 months 
because of substantial censoring due to partici-
pants having completed the trial. No adjustment 
for multiplicity of analyses was performed.
For descriptive purposes, unadjusted mean 
scores are reported according to treatment group 
at each assessment. The effect of treatment was 
evaluated with cumulative probability models (also 
called “cumulative link models”) of follow-up 
health-status scores, which do not impose distri-
butional assumptions on the outcome.20 On the 
basis of graphical analysis, a logit link was found 
to provide reasonable fit and allows the effect of 
treatment to be expressed as an odds ratio for a 
higher score with the invasive strategy, and the 
odds ratios were found to be consistent across 
the range of baseline SAQ scores at 3, 12, and 
36 months.
Blinded review of the trial data revealed non-
linear trajectories in health-status scores over time, 
with larger changes early after randomization and 
with substantial heterogeneity of individual par-
ticipants’ trajectories. We therefore used mixed 
models, within the framework of a cumulative 
probability model, that included fixed effects for 
baseline score, treatment group, time since ran-
domization, and treatment-by-time interaction, 
as well as patient-level random intercepts and 
time effects. Piecewise linear splines were used 
to model time trends, with knots at 3, 6, 12, 18, 
and 24 months for the fixed effect of time and 
knots at 6 and 12 months for patient-level ran-
dom effects. Restricted cubic splines were used 
to allow for nonlinear effects of baseline scores. 
The mixed models allowed estimation of the ef-
fects of treatment assignment on patient-specific, 
in addition to population mean, health-status out-
comes.
All models were fit with the use of Bayesian 
methods. In addition to facilitating the estima-
tion of more complex models than are produced 
with traditional frequentist methods, Bayesian 
analysis directly estimates the probability distri-
bution of the treatment effect, which can be inter-
preted as the probability of different effect sizes 
given the observed data. Weakly informative prior 
distributions (e.g., heavy-tailed t distributions 
around 0 with standard deviations of 10) were 
used for all fixed and random effects, so that 
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inference was driven predominantly by the trial 
data. The effect of treatment over time was esti-
mated for a typical patient, with a baseline health-
status score equal to the population mean and a 
random effect of 0. In addition to odds ratios 
being reported at each time point, effects were 
transformed back to the scale of the instrument 
scores by integrating over the predicted proba-
bilities of each possible value for each patient. 
As prespecified in the protocol, expected time-
averaged scores through 48 months were also 
calculated, with area-under-the-curve analyses 
used to describe the mean difference in scores 
over time. Results are presented as posterior 
means and 95% Bayesian credible intervals — 
specifically, highest posterior density intervals, 
which denote the 95% most plausible values of 
the parameter being estimated. (In Bayesian 
analysis, the posterior distribution represents the 
range and probabilities of possible values of the 
treatment effects, obtained by combining prior 
beliefs about the effect with the evidence pro-
vided by the data; the posterior mean is the mean 
of this distribution.) No P values are reported.
A key prespecified analysis was the estimation 
of the effect of treatment as a function of patients’ 
baseline angina frequency, with the a priori 
hypothesis being that there would be greater 
health-status benefits from an invasive strategy 
in patients with more frequent angina before 
randomization.12 Therefore, the above analyses 
were repeated with the SAQ Angina Frequency 
score used as a continuous variable and catego-
rized into daily or weekly angina, monthly an-
gina, or no angina and the differences between 
treatment groups calculated. To assist in the clini-
cal interpretation of the results, we conducted 
analyses (not prespecified in the statistical analy-
sis plan) estimating the probability of being 
angina-free as a function of baseline angina 
frequency. For this analysis, the model for the 
SAQ Angina Frequency score was augmented by 
inclusion of three-way interaction terms among 
treatment, time, and baseline score, to estimate 
the probability of being angina-free (SAQ Angina 
Frequency score, 100) at follow-up as a function 
of baseline score, treatment, and time. Similar 
responder analyses were performed to estimate 
the probability of having SAQ Summary and SAQ 
Quality of Life scores of 75 or higher, represent-
ing good to excellent disease-specific health status 
and quality of life, respectively. An alternative 
means of interpreting the clinical significance of 
observed changes, based on potentially clinically 
relevant intraparticipant changes in SAQ Summary 
and Angina Frequency scores, is provided in the 
Supplementary Appendix.
In the primary analysis of treatment effect, 
missing scores were assumed to be missing at 
random, conditional on treatment group and 
other available scores, because the mixed model 
implicitly imputes missing data through partici-
pants’ estimated health-status trajectories. How-
ever, because death may be an informative rea-
son for missing data, we conducted a prespecified 
sensitivity analysis of the SAQ Summary score by 
fitting a joint shared-parameter model of health 
status and survival in which the patient-level 
random effects from the model described above 
were included as covariates in a Weibull regres-
sion model of time to death.21
The sample size was driven by the clinical 
power analyses and not by the health-status analy-
ses. All analyses were conducted with SAS soft-
ware, version 9.4; R software, version 3.5.3; Stan 
software, version 2.18.1; and R packages “rstan,” 
“rstanarm,” “brms,” and “tidyverse.”22-27
R esult s
Participants
Among the 5179 participants who underwent 
randomization in the trial, we excluded those 
from five sites (481 participants) because of im-
proper form completion, as well as 51 partici-
pants in the invasive-strategy group and 30 in 
the conservative-strategy group who were miss-
ing either a baseline or all follow-up SAQ scores. 
The numbers of participants included and ex-
cluded from the analysis are shown in Figure S1 
in the Supplementary Appendix, and a compari-
son of the included and excluded participants is 
provided in Table S1. Table S2 shows the reasons 
for missing assessments, with cessation of fol-
low-up due to trial completion being most im-
portant. An additional 5% of participants died 
before the 48-month assessment. The percentages 
of intermittent skipped assessments varied from 
6 to 12% over time, with no appreciable differ-
ences between the groups with respect to how 
frequently data were missing or the reasons for 
missing data.
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The baseline characteristics of the participants 
were balanced between the treatment groups 
(Table 1). The mean age was 64 years, more than 
three quarters of participants were male, and 
the majority of participants were white. Hyper-
tension was present in 76% of participants, and 
40% had diabetes. The mean (±SD) baseline SAQ 
Summary score was 73.4±19.1 in the invasive-
strategy group and 74.8±18.8 in the conservative-
strategy group. Overall, 20% of participants had 
Table 1. Baseline Characteristics of the Patients.*
Patient Characteristic
Invasive Strategy 
(N = 2295)
Conservative Strategy 
(N = 2322)
Age at randomization — yr 64.5±9.5 64.3±9.6
Male sex — no. (%) 1748 (76.2) 1797 (77.4)
White race — no./total no. (%)† 1679/2276 (73.8) 1679/2294 (73.2)
Hypertension — no. (%) 1748 (76.2) 1768 (76.1)
Diabetes — no. (%) 906 (39.5) 930 (40.1)
Previous myocardial infarction — no. (%) 475 (20.7) 476 (20.5)
New-onset angina within 3 mo — no./total no. (%) 349/2165 (16.1) 373/2200 (17.0)
Heart failure — no. (%) 887 (38.6) 899 (38.7)
Previous cerebrovascular disease — no. (%) 195 (8.5) 170 (7.3)
Peripheral vascular disease — no. (%) 114 (5.0) 85 (3.7)
Mean BMI‡ 28.8±5.1 29.0±5.4
Degree of ischemia on stress testing, as assessed by core 
laboratory — no./total no. (%)
None 121/2291 (5.3) 126/2316 (5.4)
Mild 165/2291 (7.2) 166/2316 (7.2)
Moderate 829/2291 (36.2) 808/2316 (34.9)
Severe 1154/2291 (50.4) 1194/2316 (51.6)
Uninterpretable 22/2291 (1.0) 22/2316 (0.9)
SAQ Summary score§ 73.4±19.1 74.8±18.8
SAQ Angina Frequency score§ 80.8±20.0 82.1±19.3
Angina frequency — %
Daily or weekly 21.6 19.0
Several times per month 44.1 44.5
None in the past 4 weeks 34.3 36.6
SAQ Physical Limitation score§ 78.5±23.7 80.2±23.4
SAQ Quality of Life score§ 60.9±26.5 62.7±26.3
Rose Dyspnea Scale score¶ 1.2±1.3 1.2±1.3
EQ-5D visual analogue scale score‖ 68.8±16.9 69.2±16.7
*  Plus–minus values are means ±SD.
†  Race was reported by the participant.
‡  Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
§  On the Seattle Angina Questionnaire (SAQ), the summary score is obtained by averaging the SAQ Angina Frequency, 
SAQ Quality of Life, and SAQ Physical Limitation scores; SAQ scores range from 0 to 100, with higher scores indicating 
better health status. SAQ Angina Frequency scores of 0 to 30, 31 to 60, 61 to 99, and 100 have been shown to validly 
reflect angina that occurs daily, weekly, monthly, and no angina, respectively, as assessed with daily diaries.
¶  On the Rose Dyspnea Scale, scores range from 0 to 4, with higher scores indicating dyspnea with milder activities.
‖  On the European Quality of Life–5 Dimensions (EQ-5D) visual analogue scale, scores range from 0 to 100, with higher 
scores indicating better health status.
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daily or weekly angina, 44% had angina one to 
three times per month, and 35% had no angina 
in the month before randomization.
Primary Outcome
Unadjusted mean health-status scores for the trial 
population are shown in Figure 1. Although the 
health status in both treatment groups improved 
early after randomization, this improvement was 
greater among participants who were treated with 
an invasive strategy, a small mean difference for 
the entire population that was sustained through-
out follow-up (mean SAQ Summary scores for the 
invasive strategy vs. the conservative strategy 
were 84.7±16 vs. 81.8±17 at 3 months, 87.2±15 
vs. 84.2±16 at 12 months, and 88.6±14 vs. 
86.3±16 at 36 months). Similar magnitudes of 
mean benefit were seen for the individual SAQ 
subscales, as well as for the Rose Dyspnea Scale 
and the EQ-5D visual analogue scale. Partici-
pants in the invasive-strategy group had at least 
50% higher odds (odds ratio, ≥1.5) of having a 
more favorable SAQ Summary score than par-
ticipants in the conservative-strategy group at 
each time point throughout 4 years of follow-up 
(Table S3). Results for the individual SAQ scales, 
Rose Dyspnea Scale, and EQ-5D visual analogue 
scale were consistent with the pattern of benefit 
seen in the SAQ Summary score.
Figure 2 shows the posterior distributions for 
the effect of treatment on the expected SAQ 
Summary score of a “typical” patient (i.e., one 
with a baseline score equal to the population 
mean and a random effect of 0) in the overall 
population; similar distribution curves in co-
horts of patients with different frequencies of 
angina at baseline are shown in Figure S2. The 
mean estimated effects of an invasive strategy 
on SAQ Summary scores at different times are 
shown in Table 2. For the overall population, the 
posterior mean difference in the SAQ Summary 
score favored the invasive strategy by 4.1 points 
at 3 months and by 4.2 points at 12 months; the 
lower limits of the 95% credible intervals were 
3.2 and 3.3 points, respectively. By 36 months, 
the posterior mean SAQ improvement with the 
invasive strategy was 2.9 points, with a lower 
limit of the 95% credible interval of 2.2. When 
stratified according to baseline angina frequen-
cy, the differences were larger with the invasive 
strategy for patients with daily or weekly angina 
(8.5 points at 3 months and 5.3 points at 36 
months) or monthly angina (5.5 points at 3 
months and 3.1 points at 36 months), whereas 
patients with no angina at baseline had minimal 
to no incremental health-status benefit with the 
invasive strategy (0.1 points at 3 months and 1.2 
points at 36 months). The time-averaged differ-
ence in scores through 48 months (the mean 
difference over time) was 3.3 points in the over-
all sample, 6.3 points among patients with daily 
or weekly angina at baseline, 3.7 points among 
those with monthly angina, and 1.1 points 
among those without angina (Table S4). The dif-
ferences between the treatment groups are 
shown in Figure 3A for the SAQ Angina Fre-
quency score and in Figures S3A and S4A for the 
SAQ Summary and SAQ Quality of Life scores. 
The between-group differences were attenuated 
when the mean baseline SAQ Angina Frequency 
scores were higher than 80, indicating rare or no 
angina at randomization. Results of the joint 
analysis of the SAQ Summary score and survival, 
accounting for potential bias due to informa-
tively missing data associated with death, did 
not differ from those of the primary analysis 
(Table S5).
Probability of Being Angina-free
Figure 3B shows the probability of being angina-
free as a function of the SAQ Angina Frequency 
score at baseline. At each time point, the differ-
ence favoring the invasive strategy in the prob-
ability of being angina-free was larger among 
participants who had angina at baseline but was 
minimal among those who were asymptomatic 
before randomization. For example, among pa-
tients with a baseline SAQ Angina Frequency score 
of 50 (weekly angina), 45% of those treated in-
vasively would be expected to be angina-free at 
3 months, as compared with 15% of those treated 
conservatively. Conversely, among patients with 
a baseline SAQ Angina Frequency score of 100 
(no angina in the previous month), the majority 
remained asymptomatic at follow-up, with mini-
mal differences according to treatment strategy. 
This pattern was also observed for having a good 
to excellent (score, ≥75 points) quality of life or 
overall disease-specific health status (Figs. S3B 
and S4B). Table S6 shows the proportion of pa-
tients with small (but potentially clinically rele-
vant) and moderate-to-large changes in the SAQ 
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Summary and SAQ Angina Frequency scores ac-
cording to treatment group as a function of their 
baseline SAQ Angina Frequency scores.
Discussion
In this large strategy trial involving high-risk 
patients with stable ischemic heart disease and 
at least moderate ischemia, participants who were 
randomly assigned to the invasive treatment strat-
egy had larger improvements in disease-specific 
health status (including angina symptoms, phys-
ical function, and disease-specific quality of life) 
than did participants assigned to the conserva-
tive strategy. The modest differences favoring the 
invasive strategy in the overall trial population 
reflected differences that were confined to par-
ticipants who had had angina within the 4 weeks 
before randomization, with minimal, if any, ben-
efit among those who had been asymptomatic at 
randomization.28 The magnitude of the difference 
was largest among participants who had entered 
the trial with daily or weekly angina. Since the 
main trial showed no difference in mortality over 
a period of 3.2 years, these health-status outcome 
data should help inform detailed, patient-specific 
discussions of the risks and benefits of an inva-
sive approach in the management of stable isch-
emic heart disease. Our results provide patient-
specific estimates of treatment benefit that can 
be used as a starting point for such patient-
centered decision-making discussions.
These data substantially extend the published 
evidence from studies of the health-status ben-
efits of an invasive strategy for the management 
of stable ischemic heart disease, particularly from 
the Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation (COURAGE) 
trial.29 In our trial, we found a more sustained 
health-status benefit over time than was found 
in the COURAGE trial.5 Whether this difference 
reflects the evolution of stent technology, the 
inclusion of patients who underwent CABG, or 
the greater burden of ischemia warrants further 
investigation. Second, in our trial, in contrast to 
COURAGE and other trials of strategies for the 
treatment of stable ischemic heart disease, pa-
tients underwent randomization before invasive 
angiography was performed. This approach re-
Figure 1 (facing page). Crude Mean Health-Status Scores 
in the Overall Trial Population.
Observed mean health-status scores from randomiza-
tion through 48 months are shown. Shading represents 
the 95% confidence interval. On the Seattle Angina 
Questionnaire (SAQ), the SAQ Summary score is ob-
tained by averaging the SAQ Angina Frequency, SAQ 
Quality of Life, and SAQ Physical Limitation scores; 
SAQ scores range from 0 to 100, with higher scores 
 indicating better health status. On the Rose Dyspnea 
Scale, scores range from 0 to 4, with higher scores indi-
cating dyspnea with milder activities. On the European 
Quality of Life–5 Dimensions (EQ-5D) visual analogue 
scale, scores range from 0 to 100, with higher scores 
indicating better health status.
Figure 2. Distributions of the Expected Differences in SAQ Summary Scores from an Initially Invasive Strategy.
The posterior distribution of effect scores for a typical patient, with a baseline score equal to the population mean and a random effect 
of 0, is shown.
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moved the selection biases that result from pa-
tients not undergoing randomization if the treat-
ing physicians think they need intervention. The 
approach also supports a model of care in which 
patients are engaged in a shared decision-making 
process before angiography, a more natural break-
point in clinical workflow than taking patients 
“off the table” after diagnostic angiography has 
been performed.5
These findings should be interpreted in the 
context of several potential limitations. First, there 
were some missing health-status assessments, al-
though only approximately 10% of assessments 
were missing at any point in time, and our mixed-
effects models required only 91 patients to be ex-
cluded from the entire analysis. Second, to mini-
mize the use of cardiac catheterization in the 
conservative-strategy group, the trial excluded 
patients who had unacceptable angina despite 
maximal medical therapy; this resulted in a less 
symptomatic sample, with baseline SAQ scores 
that were more than 10 points higher (i.e., more 
favorable) than those in the COURAGE trial. Third, 
because the health-status benefits of an invasive 
strategy were present only among participants 
with angina and a large proportion of participants 
had minimal symptoms at randomization, the 
overall mean difference in scores for the entire 
trial population was much smaller than the mean 
differences among participants with more fre-
quent angina. Fourth, our results apply only to 
patients who meet the inclusion criteria of the 
trial and should not be extended to patients with 
left main coronary artery disease, acute coronary 
syndromes, or depressed ejection fractions. An 
additional concern may be that our analyses did 
not adjust for multiple comparisons. Although 
we did declare the SAQ Summary score to be our 
primary outcome, we did not define a specific time 
point to be the focus of our conclusions, given that 
we wanted to assess the magnitude and durabil-
ity of differences throughout follow-up. Lastly, 
masking patients’ treatment assignments was not 
possible in this trial.
The possibility of finding health-status ben-
efits as large as those in our trial should be con-
sidered in the context of the COURAGE trial, the 
Objective Randomised Blinded Investigation with 
Optimal Medical Therapy of Angioplasty in Sta-
ble Angina (ORBITA), and ISCHEMIA-CKD (an 
ISCHEMIA companion trial, now reported in the 
Journal,30 involving patients with coronary and 
kidney disease, in which identical health-status 
measures and analytic techniques were used). In 
the COURAGE trial, which similarly tested inva-
sive and conservative strategies, the benefits of 
an invasive approach dissipated after 12 months, 
whereas the benefits in ISCHEMIA persisted for 
more than 3 years. In ORBITA, a sham-controlled 
trial of percutaneous coronary intervention, the 
mean effect sizes (a difference of 4.4 points 
[95% confidence interval, −3.3 to 12.0] in SAQ 
Table 2. Mean Estimated Effect of an Invasive Strategy on SAQ Summary Scores.*
Month
Overall 
(N = 4617)
Daily or Weekly Angina 
 at Baseline 
(N = 934)
Monthly Angina at Baseline 
(N = 2043)
No Angina at Baseline 
(N = 1635)
points (95% credible interval)
3 4.1 (3.2 to 5.0) 8.5 (5.8 to 11.1) 5.5 (4.3 to 6.9) 0.1 (−1.2 to 1.4)
6 4.4 (3.5 to 5.3) 10.5 (7.9 to 13.2) 5.1 (3.7 to 6.4) 0.8 (−0.4 to 2.2)
12 4.2 (3.3 to 5.1) 7.3 (4.8 to 9.9) 4.8 (3.4 to 6.1) 1.7 (0.4 to 2.9)
18 3.3 (2.5 to 4.2) 6.3 (3.9 to 9.0) 3.6 (2.2 to 4.9) 1.3 (0.1 to 2.5)
24 2.8 (2.1 to 3.7) 5.0 (3.0 to 7.2) 3.5 (2.3 to 4.7) 0.6 (−0.5 to 1.7)
30 2.9 (2.1 to 3.6) 5.2 (3.2 to 7.2) 3.3 (2.2 to 4.3) 0.9 (−0.1 to 1.9)
36 2.9 (2.2 to 3.7) 5.3 (3.4 to 7.5) 3.1 (2.0 to 4.2) 1.2 (0.2 to 2.2)
42 3.0 (2.2 to 3.8) 5.5 (3.3 to 7.7) 2.9 (1.7 to 4.1) 1.4 (0.4 to 2.5)
48 3.1 (2.1 to 3.9) 5.6 (3.2 to 8.0) 2.7 (1.3 to 4.0) 1.7 (0.5 to 2.9)
*  Data are the posterior mean differences (invasive minus conservative) in SAQ Summary scores at each time point.
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Angina Frequency scores at 6 weeks) and the 
responder analyses (30% vs. 50% of participants 
were angina-free at 6 weeks in the ORBITA trial) 
were similar to what we observed.31,32 Finally, the 
ISCHEMIA-CKD trial did not show a significant 
or sustained benefit for health status with inva-
sive treatment, and it seems unlikely that a sus-
tained clinically relevant placebo effect would be 
present in the main trial but absent among pa-
tients with advanced chronic kidney disease.30
In summary, in the overall trial population of 
patients with stable ischemic heart disease and 
Figure 3. Effect of Treatment as a Function of Patients’ Baseline Angina Frequency.
Panel A shows the effect of each treatment strategy on the SAQ Angina Frequency score, measured as the estimated difference (invasive 
minus conservative) in the mean score, as a function of patients’ baseline SAQ Angina Frequency score. Panel B shows the probability 
of being angina-free (SAQ Angina Frequency score, 100) at 3, 12, and 36 months if treated with an invasive strategy (red) or a conserva-
tive strategy (blue). Shading represents 95% credible intervals.
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moderate or severe ischemia, including 35% of 
participants who had no angina at baseline, 
participants in the invasive-strategy group had 
larger improvements in angina-related health 
status than did participants in the conservative-
strategy group. The modest mean benefit of the 
invasive strategy with respect to health status 
reflected minimal benefits in asymptomatic pa-
tients and larger benefits in patients who had 
angina at baseline.
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